Abstract
The Randomized Aldactone Evaluation Study (RALES) was a randomized double-blind placebo-controlled trial designed to test the hypothesis that addition of daily spironolactone to standard therapy would reduce the risk of all-cause mortality in patients with severe heart failure as a result of systolic left ventricular dysfunction. The Data Safety Monitoring Board (DSMB) for RALES reviewed data on safety and efficacy throughout the trial using pre-specified statistical stopping boundaries for efficacy. To ensure that the data were complete, the DSMB requested successive “mortality sweeps.” At the time of these sweeps, all RALES investigators determined the vital status of participants at their clinics. Therefore, the data that the DSMB saw included a much higher percentage of the deaths than would have been observed without these sweeps. At the DSMB’s fifth meeting, the data showed 351 deaths in the placebo group and 269 in the spironolactone group for an estimated hazard ratio of 0.78 (p = 0.00018). The board recommended early termination of the trial because the observed Z-value of 3.75 exceeded the pre-specified critical value of 2.79 and the data on mortality showed consistency among subgroups and across time. The sweeps had identified 31 deaths that likely would not have been reported by the time of the meeting. Subsequent data collection identified an additional 46 deaths that had occurred by the time the study ended. Even when the endpoint of a randomized clinical trial is mortality, routine methods of data collection and reporting are unlikely to identify all events in a timely manner. The experience from RALES provides an example of the importance of active follow-up of patients to ensure that a DSMB is observing a high proportion of the events that have actually occurred.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Julian DG, Cowan JC, McLenachan JM. 1998. Cardiology, 7th Edition. WB Saunders, London.
Criteria Committee of the New York Heart Association: Diseases of the Heart and Blood Vessels (Nomenclature and Criteria for Diagnosis). 1964. Little, Brown, Boston.
Gradman AH, Deedwania PC. 1994. Predictors of mortality in patients with heart failure. Cardiol Clin 12:25–35.
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, et al. 1986. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 314:1547–1552.
The CONSENSUS Trial Study Group. 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 316:1429–1435.
The RALES Investigators. 1996. Effectiveness of spironolactone added to an angiotensinconverting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78:902–907.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J for The Randomized Aldactone Evaluation Study Investigators. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 341:709–717.
O’Brien P, Fleming T. 1979. A multiple testing procedure for clinical trials. Biometrics 35:549–556.
Lan K, DeMets D. 1983. Discrete sequential boundaries for clinical trials. Biometrika 14:1927–1931.
Wittes J, Palensky J, Asner D, Julian D, Boissel J, Furberg C, Kulbertus H, Pocock S, Roniker B. 2001. Experience collecting interim data on mortality: an example from the RALES study. Curr Control Trials Cardiovasc Med 2:59–62.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Wittes, J., Boissel, JP., Furberg, C.D., Julian, D.G., Kulbertus, H., Pocock, S. (2006). Stopping the Randomized Aldactone Evaluation Study Early for Efficacy. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_13
Download citation
DOI: https://doi.org/10.1007/0-387-30107-0_13
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-20330-0
Online ISBN: 978-0-387-30107-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)